SuperworthOrganogenesis profit margin ORGO
Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.
- Net margin, 12 months
- −18.4%
- Operating margin, 12 months
- −7.8%
- Net margin on a year earlier
- −16.5 pts
- Peer median
- 11.6%
Over the twelve months to Jun 30, 2026, Organogenesis kept −18.4% of its revenue as net profit, with an operating margin of −7.8%.
Five years earlier its net margin was 16.1%.
The median for 10 large drugmakers of a similar size is 11.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 6.6% | 7.9% | n/a |
| FY2024 | 0.2% | −0.3% | 76.0% |
| FY2023 | 1.1% | 2.9% | 75.4% |
| FY2022 | 3.4% | 4.9% | 76.7% |
| FY2021 | 20.2% | 15.5% | 75.6% |
| FY2020 | 5.2% | 8.0% | 74.2% |
| FY2019 | −15.5% | −11.3% | 70.9% |
| FY2018 | −33.5% | −26.7% | 64.4% |
| FY2017 | −1.1% | −2.8% | 69.2% |
| FY2016 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −18.4% | −16.5 pts | −7.8% | |
| Q1 FY26 | 0.5% | +4.0 pts | 0.5% | |
| Q4 FY25 | 6.6% | +6.4 pts | 7.9% | |
| Q3 FY25 | 0.2% | +1.8 pts | −1.8% | |
| Q2 FY25 | −1.9% | +1.8 pts | −5.3% | |
| Q1 FY25 | −3.5% | −4.8 pts | −5.3% | |
| Q4 FY24 | 0.2% | −1.0 pts | −0.3% | |
| Q3 FY24 | −1.6% | −4.5 pts | −2.8% | |
| Q2 FY24 | −3.7% | −5.9 pts | −2.4% | |
| Q1 FY24 | 1.3% | −1.6 pts | 2.9% | |
| Q4 FY23 | 1.1% | −2.3 pts | 2.9% | |
| Q3 FY23 | 2.9% | −9.9 pts | 5.0% |
Against its peers
Companies in Drug Manufacturers - General nearest Organogenesis' size, closest first, today.
| Company | Profit margin |
|---|---|
| ORGOOrganogenesis | −18.4% |
| NATRNatures Sunshine Products | 3.7% |
| LFVNLifevantage | 2.8% |
| SPROSpero Therapeutics | 15.7% |
| ATNMActinium Pharmaceuticals | n/m |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| COLLCollegium Pharmaceutical | 5.9% |
| Peer median | 11.6% |
Where Organogenesis ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Organogenesis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.